Precision Peptide Company Profit Margin

Precision Peptide Company (BPC.CN) currently reports a profit margin of -4206.2% as of July 2026. That compares with -23694.23% in the prior-year period — up 82.2% year over year. That is below the sector sector average of 13.16%. Use the charts on this page to explore Precision Peptide Company's profit margin history and peer comparisons.

Precision Peptide Company's profit margin increased from -23694.23% to -4206.2% — a 82.2% year-over-year increase (period ending July 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Precision Peptide Company's profit margin of -4206.2% is lower than the its sector sector average of 13.16%. That is roughly 32053.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Precision Peptide Company's current -4206.2% should be judged against industry norms (sector average: 13.16%) and against BPC.CN's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -4206.2%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 13.16%. From there, open related valuation or income-statement pages for Precision Peptide Company, and consider following BPC.CN for alerts when major investors trade the stock.